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1. Background
The South African Childhood Asthma Working Group 
(SACAWG), a sub-committee of the Allergy Society of 
South Africa (ALLSA), first published its guideline for the 
management of chronic asthma in children and adolescents 
in 1992.1 The guideline was revised in 19942 and 2000.3 In 
the past decade, there have been significant advances in the 
management of asthma; these include treatment based on 
level of control, newer treatment options, new formulations of 
inhaled corticosteroids, and availability of low-cost spacers for 
delivering inhaled drugs.
The current revision was prompted by: (i) a need to expand 
the sections on diagnosis and treatment to include children 
≤5 years old; (ii) the revised classification of asthma based 
on level of control; (iii) an ongoing need to emphasise the 
use of controllers (previously referred to as preventers) as 
the foundation of asthma treatment; and (iv) the positioning 
of newer treatment options for asthma (evidence-based 
approach), including combination treatment (inhaled 
corticosteroid (ICS) plus a long-acting β2-agonist (LABA)), 
leukotriene receptor antagonists, sublingual immunotherapy, 
omalizumab and macrolides.
The objectives of this guideline are to promote a better 
standard of treatment based on advances in the understanding 
of the pathophysiology and pharmacotherapy of asthma, and 
to encourage uniformity in the management of asthma.
2. Methodology
This 2009 asthma guideline update was undertaken after a 
meeting with a working group constituted by ALLSA. The 
working group is chaired by Professor Cas Motala.
The working group meetings were held in June 2008. 
Four task groups, each headed by a leader, were constituted: 
(i) Asthma diagnosis and assessment of level of control; 
(ii) Environmental control measures and immunotherapy; 
(iii) Pharmacotherapy: corticosteroids and steroid/LABA 
combinations; (iv) Pharmacotherapy: New treatments including 
leukotriene modifiers, anti-IgE and macrolides. The task groups 
were charged with reviewing the available scientific literature 
and assigning evidence levels according to the methodology 
utilized in current guideline documents: Categories A, B, C 
and D based on the strength of evidence levels (Appendix B). 
Subsequently, an editorial board, consisting of the chairperson 
and leaders of the task groups, was convened. The working 
group is aware of the trend toward application of GRADE4 
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Objective. To revise the guideline for the diagnosis and 
management of chronic asthma in children in view of 
the following considerations: the existing South African 
Childhood Asthma Working Group (SACAWG) guideline 
was produced 10 years ago; diagnosis of asthma in young 
children remains a challenge; evidence-based treatment is the 
new paradigm; new treatment approaches to achieving and 
maintaining control; therapeutic roles of several medications 
have evolved; more studies and data on treatment in young 
children; new medications and formulations; a change of 
emphasis in assessing asthma control to guide treatment 
changes. The main aim of the guideline is to promote a 
better standard of treatment based on understanding of 
the pathophysiology and pharmacotherapy of asthma, and 
encouraging uniformity in asthma management.
Evidence. A detailed literature review by a working group 
of clinicians from relevant disciplines. The strategies 
recommended are classified according to the evidence 
category in Appendix B, and denoted as Evidence A, B, C  
and D.
Recommendations. These include an appropriate diagnostic 
approach, environmental control measures, treatment options, 
definition of asthma control, and strategies to achieve control.
Endorsement. The guideline document was endorsed by the 
South African Thoracic Society (SATS), the National Asthma 
Education Programme (NAEP), the South African Paediatric 
Association (SAPA) and the South African Academy of 
Family Practice.
S Afr Med J 2009; 99: 898-912.
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technology and will consider utilising this methodology in the 
future.
The working group met again in July 2009 to discuss the 
draft guideline document. Thereafter, the editorial board was 
tasked to finalise the document for publication. This project 
was sponsored by ALLSA. 
3. Disease profile
Asthma is the most common chronic childhood disease, 
affecting 10 - 20% of South African children.5 The burden of 
asthma affects the patients, their families, and general society 
in terms of lost work and school days, impaired quality of life, 
hospitalisations and mortality. Asthma typically begins in early 
life, and is often triggered by viral infections or environmental 
factors including allergens. Airway inflammation and airway 
hyper-responsiveness are the hallmarks of the disease. 
Characteristic symptoms include recurrent episodes of 
wheezing, breathlessness, chest tightness and coughing. In 
children ≤5 years, the clinical symptoms are variable and 
nonspecific. Furthermore, neither airflow limitation nor airway 
inflammation are possible to assess routinely in this age 
group. Diagnosing asthma in young children may therefore be 
difficult.
The goal of asthma treatment is to achieve control of the 
disease for prolonged periods with appropriate regard for the 
safety and cost of treatment required to achieve this. Defining 
satisfactory current clinical asthma control in children ≤5 
years is problematic since it is almost exclusively dependent 
on reports from family/caregivers who may be unaware of or 
underreport the presence of asthma symptoms.
Recommendations in this guideline are based on currently 
available evidence. Health practitioners should strive to 
achieve the best possible therapy for each of their patients 
through motivation and education of parents and health 
care professionals, to ensure that all patients have access to 
appropriate medication.
4. Diagnosis
Asthma should be diagnosed in a child with chronic/recurrent 
wheeze with or without cough (owing to bronchoconstriction) 
triggered by multiple factors including viral infections, 
allergens, irritants (pollution), exercise and sudden emotional 
changes (e.g. crying, laughing) and which responds to an 
inhaled bronchodilator. Features supporting the diagnosis are 
a family or personal history of atopy, night cough, exercise-
induced cough and/or wheeze and seasonal variation in 
symptoms. In children, allergy is often the main trigger that 
determines the severity of the disease. Early sensitisation, 
severe atopy and synergistic interaction between atopy and 
infections are risk factors for persistent asthma.6 Cough variant 
asthma is a rare form of asthma which presents with cough 
but no wheeze and no evidence of airway obstruction on 
spirometry.7,8
4.1 Children older than 5 years
A careful history and physical examination, together with 
objective evidence of reversible airflow obstruction after 
administration of a short-acting β2-agonist (SABA) (an increase 
in forced expiratory volume in 1 second (FEV1) >12% or in peak 
expiratory flow rate (PEF) >15% after 10 minutes), will in most 
instances confirm the diagnosis. Monitoring symptoms and 
PEF using a diary card is also useful for making the diagnosis; 
diurnal PEF variability >20% is highly suggestive of asthma. 
Conditions that need to be considered when the diagnosis of 
asthma is uncertain are listed in Table I.
4.2 Children 5 years and younger
The diagnosis of asthma in early childhood is challenging and 
has to be based largely on clinical judgement (assessment 
of symptoms and physical findings).  Since the use of the 
label ‘asthma’ for wheezing in children has important clinical 
implications, it must be distinguished from other causes of 
persistent and recurrent wheeze (Table II). 
Episodic wheezing and cough is very common even in 
children who do not have asthma, and particularly in those <3 
years old. Three categories of wheezing have been described in 
children ≤5 years (retrospective epidemiological classification9): 
transient early wheezing, persistent early-onset wheezing, and 
late-onset wheezing. Despite this epidemiological classification, 
the diagnostic approach to these patients is poorly described, 
especially in low- and middle-income countries.
Table I. Differential diagnosis of asthma in children older 
than 5 years
Hyperventilation syndrome and panic attacks
Vocal cord dysfunction
Upper airway obstruction and inhaled foreign bodies
Other forms of obstructive lung disease (e.g. cystic fibrosis)
Non-respiratory causes of symptoms (e.g. left ventricular 
failure)
Table II. Differential diagnosis of asthma in children 5 
years and younger
Infections
Post-viral wheezing
Tuberculosis (e.g. glandular compression of airways)
HIV disease (e.g. lymphocytic interstitial pneumonia)
Congenital/perinatal problems
Tracheomalacia
Cystic fibrosis
Chronic lung disease of the newborn
Congenital malformation causing narrowing of the intrathoracic 
airways
Primary ciliary dyskinesia syndrome
Immune deficiency
Congenital heart disease (e.g. L-R shunts)
Mechanical problems
Foreign body aspiration
Gastro-oesophageal reflux disease (GORD)
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A simple clinical index (asthma predictive index) based 
on the presence of a wheeze before the age of 3, and the 
presence of 1 major risk factor (parental history of asthma or 
eczema) or 2 of 3 minor risk factors (eosinophilia, wheezing 
without colds, and allergic rhinitis), has been shown to predict 
the occurrence of asthma in later childhood in children in 
developed countries.10 While useful to diagnose asthma in 
large epidemiological studies in Europe and America (Evidence 
B), this finding has not been applied in the context of African 
children, who have less atopy.
A recent publication categorised wheeze in young children 
into 2 broad groups: episodic (viral) wheeze and multi-trigger 
wheeze.11 The group of children who have multi-trigger 
wheeze have symptoms precipitated by factors other than viral 
infections (such as allergens and exercise) and are likely to be 
asthmatic.
The diagnosis of preschool asthma should be based on a 
composite set of diagnostic criteria and, while no tests diagnose 
asthma with certainty in young children, the following may be 
considered as useful adjuncts in making a diagnostic decision:
4.2.1   Clinical features
The categories of symptoms and therapeutic responses listed 
in Table III are highly suggestive of asthma (based on current 
evidence and clinical experience).
4.2.2   Modified bronchodilator response test (MBR)12 
(Evidence D)
In this test, a patient suspected of having asthma (usually a 
young child with persistent or recurrent wheezing) is given 
a bronchodilator by nebuliser or metered-dose inhaler (MDI) 
with a spacer, and symptoms/signs are evaluated 10 - 15 
minutes later. Asthmatics usually demonstrate a significant 
clinical response to a bronchodilator, as measured by reduction 
in wheeze or respiratory rate or improvement in air entry. 
Some children with viral-induced wheeze may also respond, so 
the test forms part of an assessment for asthma and is not the 
sole criterion for diagnosis.
4.2.3   Lung function testing
Lung function testing is useful for aiding the diagnosis of 
asthma in children >5 years. In general, they do not have a 
diagnostic role in younger children because of their inability to 
perform reproducible expiratory manoeuvres. Lung function 
testing for infants13 and young children are only possible in 
specialised centres, and are mainly used for research purposes.
5. Goals and principles of management
5.1 Goals
The goal of asthma therapy is asthma control. Control implies 
that the asthmatic child is able to lead a normal and physically 
active life. The criteria for ‘normal life’ are to:
•    be completely free from any symptoms, i.e. cough, wheeze 
and breathlessness
•    attend school regularly and participate fully in all school 
activities, including sport
•   sleep restfully, free from night-time cough and/or wheeze
•   grow and develop normally
•    minimise the number of attacks of acute asthma and avoid 
hospitalisation
•   avoid or minimise medication-related side-effects.
5.2 Principles
A comprehensive therapeutic approach is required to meet the 
above objectives, which includes the following:
•   early diagnosis and objective assessment of severity
•    control of the environment to exclude cigarette smoke and 
reduce exposure to triggers such as viral infection and 
allergens
•    optimal use of medications to limit side-effects and cost, 
using the most appropriate delivery system
•    follow-up and regular re-evaluation (clinical evaluation and 
quality of life)
•   patient and parent education.
6. Environmental control
Avoidance of allergens (based on history and allergy testing) 
and pollutants is recommended when there is a clear 
association between exposure and symptoms. Recommended 
avoidance measures are discussed below.
6.1 Indoors
6.1.1 Tobacco smoke/other pollutants
Smoking should not be allowed in the home, and active steps 
should be taken to inform parents of the problem, encouraging 
Table III.  Features suggestive of asthma in children <5 
years
Evidence A
Exercise-induced cough or wheeze
Cough at night
Symptoms persisting after the age of 3 years
Evidence B
Absence of seasonal variation
Symptoms worsening with certain exposures
Colds repeatedly going to the chest
Response to a bronchodilator
Response to a course of steroid
Concomitant rhinitis, eczema or food allergies
Family history of allergy or asthma
Evidence C
Wheezing more than 1 month
Evidence D
Modified bronchodilator response test
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smokers to quit. Smoking during pregnancy should be strongly 
discouraged as the evidence indicates that in utero exposure to 
tobacco smoke is associated with a higher risk of developing 
wheezing early in life.
Other sources of biomass fuel exposure, such as open fires 
for cooking or heating, may trigger asthma or cause more 
severe asthma. Fluted chimneys and good ventilation in homes 
should be encouraged. Children should be kept away from 
open flames or fumes, e.g. a mother should avoid putting her 
baby on her back while cooking over open flames.
6.1.2 Indoor allergens14
A detailed history should identify which allergens are likely 
to be triggers of asthma symptoms. If there is uncertainty 
after taking a history, and the child has persistent asthma, 
then specific allergen testing by skin prick test or specific 
immunoglobulin E (IgE) is indicated. There is no evidence 
to support avoidance of allergens for primary prevention of 
asthma.
•    House dust mites. Mattress, pillow and duvet covers with 
mite-impermeable characteristics are recommended, but 
mites will accumulate on mattress covers if these are not 
regularly washed15 (Evidence B). Bedding should be washed 
regularly at temperatures >60°C. Rooms should be well 
ventilated. Where possible, carpets should be removed from 
the living areas and especially the bedrooms. Acaricides are 
ineffective. Other sources of house dust mites should also be 
considered, e.g. fluffy toys and feather pillows.
•    Cockroaches. Cockroach allergy is widespread in South 
Africa. Cockroaches may be a cause of ongoing airway 
inflammation, and sensitivity to cockroaches is a risk factor 
for more severe asthma. Obsessive cleaning, bait stations 
and boric acid indoors can reduce cockroach numbers16 
(Evidence B).
•    Pets. Asthmatics known to be allergic to dogs or cats should 
avoid contact with them. Cat allergens are notoriously 
difficult to eliminate and may persist for several months 
after the cat has been removed from the home. Use of a dust 
cloth is three times more effective in reducing allergen levels 
than vacuuming with a brush attachment17 (Evidence B).
•    Mould. Obvious sources of indoor mould in bathrooms, 
kitchens and damp areas of the home should be dealt with 
by proper plumbing, damp-proofing, mould-repellent 
paint and sodium hydroxide sprays. Products containing 
hypochlorite are effective in cleaning homes, achieving 
a low reduction in fungi, and improving quality of life 
– which was statistically significantly better than in a control 
group18 (Evidence B).
6.2 Outdoors
6.2.1 Outdoor allergens
Moulds are important sources of outdoor allergens, and 
sensitive children are advised to avoid exposure to mouldy 
places, e.g. farms, forests, compost heaps and parks, 
particularly in autumn, winter and spring. Grass pollens may 
be implicated in perennial asthma because of the particularly 
long grass season in South Africa.
7. Treatment
Pharmacotherapy is the cornerstone of asthma management, 
with appropriate medication and delivery devices to meet 
patients’ needs and circumstances. When asthma is first 
diagnosed, it is convenient for initiation of treatment to classify 
it as mild intermittent or chronic persistent asthma that is 
mild, moderate or severe (Table IV).3 However, the severity 
of asthma is variable, does not predict response to treatment, 
and is of little value in patients already on treatment. Periodic 
assessment of asthma control (Table V)19 (www.ginasthma.com) 
and review of management are more relevant. Asthma severity 
assessment is used to initiate therapy, while asthma control is 
determined to monitor and adjust therapy.
7.1 Assessment of severity to initiate therapy
The method of assessment presented conforms to international 
assessment criteria. The following points should be noted:
•    The assessment of severity is used to assign a child to a 
particular treatment group only as a starting point.
•    The assessment of severity refers to a child’s symptoms 
and lung function (PEF or FEV1) between acute episodes in 
a patient who is not receiving long-term therapy. Severity 
can also be measured, once asthma control is achieved, by 
the step of care (i.e. the amount of medication) required to 
maintain control.
•    One or more features must be present to assign a grade 
of severity; a patient must be assigned to the most severe 
grade in which any feature occurs.
•    In practice, about 70% of childhood asthmatics will fall 
into the mild persistent category, 25% into the moderate 
persistent group, and 5% into the severe persistent 
category.
7.2 Assessment of asthma control
Control refers to the degree to which the manifestations 
of asthma are minimised by therapeutic intervention and 
the goals of therapy are met. After therapy is initiated, the 
emphasis for clinical management changes to the assessment of 
asthma control (Table V). The level of asthma control will guide 
decisions either to maintain or to adjust therapy, i.e. step up 
if necessary, or step down if possible. Asthma control may be 
assessed clinically (symptoms, physical findings, reliever use), 
and by measurement of lung function and fractional exhaled 
nitric oxide (FENO) in certain situations.
7.2.1 Clinical assessment
Clinical assessment includes the frequency of daytime and 
nocturnal symptoms, the extent of limitation of activities, and 
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the need for reliever treatment (Tables V and VI). Patient-
centred questionnaires such as the Childhood Asthma Control 
Test (cACT) are very useful for identifying children who 
are uncontrolled.20 The cACT has been promoted for the 
assessment of asthma control in children ≥4 years old. The 
cACT has 7 questions regarding asthma symptoms present in 
the previous 4 weeks. The first 4 questions are completed by 
the child, while the last 3 are completed by the parent. A score 
of 20 or more is judged to be well-controlled asthma.
7.2.2 Spirometry
Spirometry (flow-volume loop) can only be performed reliably 
in children >5 years old. The most commonly used parameters 
derived from the volume/time plot are FEV1 and the forced 
vital capacity (FVC). The most commonly used parameters 
derived from the flow/volume plot are PEF and the maximum 
mid-expiratory flow rate (MMEF).  FEV1 and PEF are utilised 
most frequently for assessing asthma control.
Spirometry should be performed:
•   at the initial assessment
•    after treatment is initiated and symptoms and PEF have 
stabilised
•    during periods of progressive or prolonged loss of asthma 
control
•    at least every 1 - 2 years, more frequently depending on 
response to therapy
Low FEV1 indicates current obstruction and is a useful 
measure of risk for exacerbations, although it must be 
emphasised that even children who have normal lung function 
experience exacerbations. PEF can be read directly off the 
flow-volume loop or it can be measured with a peak flow 
meter which can easily be used at home to monitor lung 
function. PEF has limitations in that it is effort-dependent; PEF 
changes do not always reflect changes in lung function, and 
are generally a late indicator of loss of asthma control.  Among 
patients with mild intermittent or mild persistent asthma, PEF 
monitoring has no advantage over symptom monitoring.21 
Short-term daily PEF monitoring, however, should be 
considered for patients who have moderate to severe persistent 
asthma or a history of severe exacerbations (it may be helpful 
for assessing the severity of obstruction and evaluating 
response to bronchodilator therapy) and for patients who 
poorly perceive airway obstruction or worsening asthma. 
7.2.3   Exhaled nitric oxide (FENO)
FENO is not a routine test of asthma control. For most 
children, monitoring of exhaled NO offers no benefit over 
Table IV.  Classification of asthma severity based on symptoms and PEF in patients presenting for the first time on no 
treatment
  Mild intermittent  Mild persistent       Moderate persistent           Severe persistent
Symptoms ≤2 days/week  <2 days/week but not daily      Daily symptoms            Continual symptoms
Night-time  ≤2 incidents/month  3 - 4 incidents/month      >1 incident/week but            Frequent
symptoms            not nightly
PEF (predicted) ≥80% predicted  ≥80% predicted       >60 - ≤80%            ≤60%
PEF variability <20%   20 - 30%        >30%             >30%
Table V. Levels of asthma control (Global Initiative for Asthma (GINA) 2007)19
           Uncontrolled
    Controlled  Partly controlled   (≥3 features of partly
    (all of the   (any measure present  controlled asthma in any
Characteristics   following)  in any week)   week)
Daytime symptoms:   <2/week   >2/week    >2/week
wheezing, cough, 
difficult breathing 
Limitation of activities  None   Any    Any
Nocturnal symptoms/awakening None   Any    Any
Need for reliever/rescue treatment <2/week   >2/week    >2/week
Lung function* (PEF/FEV1)  Normal   <80%    <80%
predicted or personal best (if known)
* Applicable to children >5 years old.
Table VI. Routine asthma follow-up questions
1.    How often have you had asthma symptoms in the last week?
2.    How often in the last week have you woken at night because 
of asthma symptoms?
3.    How often in the last week have asthma symptoms limited 
your ability to be active?
4.    How many puffs of reliever medicine have you used in the 
last week?
5.    Have you missed any days of school/work in the last month 
because of asthma?
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clinical monitoring. It may, however, have value in certain 
circumstances such as a child with difficult-to-control asthma. 
FENO values have been shown to increase before the onset of 
symptoms or loss of control and monitoring may, therefore, 
be used to predict loss of control.22 It may also be useful for 
assessing compliance with anti-inflammatory therapy. 
7.3 Principles of medication
When selecting medication for an asthmatic patient, the 
following principles apply:
•    regular anti-inflammatory medication is indicated for 
persistent asthma
•   inhaled therapy is preferable
•   drugs are classified as: 
•    relievers – short-acting bronchodilators with rapid onset 
of action that provide acute relief of symptoms
•    controllers –  drugs with anti-inflammatory and/or a 
sustained bronchodilator action.
7.4 Route of administration
Inhaled therapy is the cornerstone of asthma treatment for 
all children. Most children can be taught to use inhaled 
therapy effectively. Considerations in choosing an inhaler 
device include the efficacy of drug delivery, cost, safety, ease 
of use, convenience and efficacy in a specific age group.23,24 
A metered dose inhaler (MDI) with spacer is preferable to 
nebulised therapy because of convenience, more effective lung 
deposition, fewer side-effects and lower cost.25,26 
Spacers retain large drug particles that would be deposited 
in the oropharynx, so reducing oropharyngeal side-effects 
and systemic absorption and availability of inhaled drug. 
This consideration is especially important for ICS with poor 
first-pass metabolism such as beclomethasone dipropionate 
(BDP) and budesonide. Commercially produced spacers with 
well-characterised drug output characteristics, or a homemade 
spacer device made from a 500 ml plastic cold-drink bottle, 
are preferable.27  A child’s inhalation technique should be 
observed, and corrected if necessary, at the health-care 
consultation.
An MDI with a spacer is as effective as, or more effective 
than, nebulised treatment for of acute, severe asthma 
exacerbations.25,26  Nebulisers have imprecise dosing, are 
expensive, waste large amounts of drug into the surrounding 
air, are time-consuming to use and care for, and require 
maintenance. They are mainly reserved for children who 
cannot use other inhalation devices. In general, nebulisers 
should be discouraged for home use and rather utilised 
in settings where oxygen administration is necessary and 
available. A general inhaler strategy for children is given in 
Table VII.
7.5 Relievers
These include SABAs (Evidence A) and anticholinergics. Short-
acting xanthines are not recommended in the maintenance 
treatment of asthma.
7.5.1 Short-acting β2-agonists
SABAs are generally used on an as-needed basis. Their use 
can be minimised by the optimal use of anti-inflammatory 
agents and controllers. SABA inhalers provide relief from acute 
symptoms of asthma.
7.5.2 Anticholinergics (ipratropium bromide)
These drugs work by inhibiting vagally mediated 
bronchoconstriction. They are less potent bronchodilators 
than inhaled β2-agonists and in general have a slower onset of 
action (30 - 60 minutes to maximum effect). They may be used 
in patients who cannot tolerate β2-agonists or as adjunctive 
bronchodilator treatment in patients who do not obtain 
adequate symptom relief during acute asthma. There is no 
evidence for the long-term use of ipratropium bromide in the 
management of asthma.
7.6 Controllers
Controller therapy is recommended for all patients with 
persistent asthma. ICSs are the most effective controller 
therapy for asthma (Evidence A). LABAs have prolonged 
bronchodilatory action, but have weak anti-inflammatory 
(controller) effects. Leukotriene receptor antagonists (LTRAs) 
also have anti-inflammatory effects via different pathways 
to ICSs. Sustained-release (SR) theophyllines have also been 
shown to have weak anti-inflammatory effects at doses lower 
than those required for bronchodilatation.
7.6.1 Inhaled corticosteroids (ICSs)
ICSs are the most effective medication for controlling 
symptoms, reducing the number of asthma-related 
hospitalisations, improving lung function, reducing the 
frequency of exacerbations, improving quality of life and 
reducing bronchial hyper-responsiveness19,28-34 (Evidence A).
Inhaled therapy via an MDI with spacer is preferable to 
nebulised therapy because of the convenience, more effective 
Table VII. Choice of inhaler device for children
Age group   Preferred device
Younger than 4 years  Pressurised metered-dose inhaler 
plus spacer with face mask 
4 - 6 years   Pressurised metered-dose inhaler 
plus spacer with mouthpiece
Older than 6 years   Pressurised metered-dose inhaler 
with spacer and mouthpiece, 
or dry powder inhaler (DPI), 
or breath-actuated pressurised 
metered-dose inhaler 
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lung deposition, fewer side-effects and lower cost (Evidence 
A). For children >5 years old, a dry powder inhaler (DPI) or 
breath-actuated pressurised MDI may be alternatives to an 
MDI with spacer.
A number of different ICS preparations are available (Table 
VIII). Most ICSs should be given twice daily, but budesonide 
and ciclesonide are approved for use once daily in children 
with mild asthma. The most important determinant of 
appropriate dosing is the patient’s response to therapy. ICS 
dose should be adjusted according to the level of control 
attained. Once control of asthma is achieved, the dose of 
medication should be carefully titrated to the minimum dose 
required to maintain control, thus reducing the potential for 
adverse effects.
Side-effects
Most studies evaluating the systemic effects of ICS suggest 
that clinically effective doses of ICS are safe and the potential 
risks are well balanced by the clinical benefits19,33,34 (Evidence 
A). However, studies using higher doses have been associated 
with detectable systemic effects on both growth and the 
hypothalamo-pituitary axis (HPA). Although there are fewer 
studies in children <5 years, the available data are similar 
to those from older children.19,34,35 Generally, low doses of 
ICS have not been associated with any clinically important 
adverse systemic effects in clinical trials, and long-term use is 
considered safe.19,34-36 Local side-effects, such as hoarseness and 
candidiasis, are rare in children when a spacer is used.
Children older than 5 years
Most children are controlled on low daily doses of ICS (100 -  
200 g budesonide or equivalent (Table VIII). Some children 
require higher doses (400 µg/day) for control and for 
protection against exercise-induced symptoms. Clinical 
improvement occurs rapidly within 1 - 2 weeks, although 
maximum improvement may occur only after many weeks. 
Symptoms may recur after stopping ICS, with control 
deteriorating within weeks.
Children younger than 5 years
Several studies of ICS in young children with asthma have 
shown similar clinical effects as in older children, including 
increases in lung function and number of symptom-free days, 
reduction in symptoms, need for additional medication, 
caregiver burden, systemic glucocorticosteroid use, and 
exacerbations.30-32,34-36 A systematic review of randomised 
double-blind controlled trials of ICSs in preschool children 
with wheeze showed statistically significant improvements in 
symptoms, exacerbation rates, lung function and airway hyper-
responsiveness.31 Of note is that exacerbations were reduced by 
almost 40%.31 However, the dose-response relationships have 
been less well studied. Use of ICSs for up to 2 years has not 
been shown to induce remission of asthma; symptoms usually 
return when treatment is stopped.30
The clinical benefits of ICS for episodic, viral-induced 
wheeze are controversial. Systematic reviews found that 
episodic high-dose ICSs provide some benefit, reducing the 
need for oral corticosteroids by 50%; however, no effect on 
hospitalisation rates or duration of symptoms was found. 
Maintenance treatment with 400 µg/day of budesonide 
equivalent does not reduce the number or severity of wheezing 
episodes in episodic, viral-induced wheeze.37,38
Intermittent use of ICSs in preschool children with episodic 
viral wheeze at the time of symptoms does not reduce the 
risk of persistent wheeze at the age of 6 years, and symptoms 
return when steroid therapy is discontinued.39 Therefore, 
the use of intermittent ICS for episodic wheeze cannot be 
recommended.
Children younger than 2 years
There is a paucity of data on the efficacy and safety of ICS in 
children <2 years old.34-36 In addition, wheezing caused by viral 
infections is very common in this age group but often resolves 
spontaneously or remits with age. In general, ICSs should only 
be used if symptoms are particularly troublesome and there 
is a clear response to treatment. As for older children, ICSs 
should be stepped down as control is achieved, so that the 
lowest ICS dose for control of symptoms is used.
7.6.2 Long-acting inhaled β2-agonists (LABAs)
Children older than 5 years
A Cochrane review of 25 trials of 5 572 children reported 
that addition of LABAs did not significantly reduce the risk 
of asthma exacerbations requiring rescue systemic steroids, 
hospitalisation or duration of symptoms, but improved lung 
function compared with ongoing treatment with a similar 
dose of inhaled corticosteroids.40 There was no evidence of 
Table VIII. Estimated equipotent daily dosage of ICS for children 
Drug  Low daily dose (µg)  Medium daily dose (µg)  High daily dose ( µg)
Beclomethasone
dipropionate 100 - 200    200 - 400    >400
Budesonide* 100 - 200    200 - 400    >400
Ciclesonide * 80 - 160    160 - 320    >320
Fluticasone 100 - 200    200 - 500    >500
*Approved for once-daily dosing in patients with mild asthma.
As CFC preparations are taken off the market, medication inserts for HFA preparations should be carefully reviewed for the equivalent correct dosage.
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increased serious side-effects or withdrawals with the addition 
of LABAs.
The effect of LABAs added to ICSs (7 studies, 1 021 children) 
compared with a higher dose of ICS also reported no difference 
in the incidence of asthma exacerbations requiring oral steroids 
or in the rate of hospitalisation for asthma. However, lung 
function was significantly improved in children on LABAs.40 
Studies have reported improvements in peak flow and lung 
function with the addition of a LABA.43-47 However, the effect 
on symptoms, need for rescue medication and frequency 
of exacerbations have been less consistent.41,42 The available 
paediatric studies suggest a modest improvement in lung 
function in children in whom LABAs are added to an ICS.40-47
LABAs are therefore currently positioned for maintenance 
treatment of children with asthma only in combination with 
inhaled corticosteroids. Combination products (i.e. those 
containing an inhaled corticosteroid and a LABA in the same 
device) are preferable to administration via separate inhalers. 
Fixed combination inhalers ensure that the LABA is always 
accompanied by an ICS. Combination products available in 
South Africa are shown in Table IX.
Side-effects
LABAs are generally well tolerated in children. Side-effects are 
similar in type and frequency to those of SABAs, and include 
muscle tremor, headache and palpitations. An increased risk of 
severe asthma exacerbations and mortality has been reported, 
particularly when used as monotherapy; therefore, LABAs 
should never be used without an ICS.19,41,42
Children younger than 5 years
The effect of LABAs or combination products has not been 
adequately studied in children ≤5 years old. There are no 
published double-blind randomised placebo-controlled trials 
on the addition of LABAs to ICSs in this age group. LABAs are 
currently approved for use in South Africa in children >4 years 
old. Therefore, LABAs cannot be recommended at present for 
children <4 years old.
7.6.3 Leukotriene receptor antagonists/leukotriene 
modifiers
Leukotriene receptor antagonists (LTRAs) are an accepted 
treatment option for childhood asthma. They have a rapid 
onset of action (within 1 - 3 hours),48 are administered orally, 
treat asthma via a different pathway to other currently 
available medications (specific cysteinyl leukotriene receptor 
antagonists), and have been shown to be effective for aspirin-
sensitive asthma.49
Side-effects
No significant safety concerns have been demonstrated 
for leukotriene modifiers in children. Headache and 
gastrointestinal upset are the most commonly encountered 
side-effects; skin rashes or flu-like symptoms are much less 
common.50,51
Children older than 5 years
LTRAs provide clinical benefit in children >5 years old at all 
levels of severity52-56 (Evidence B), but generally less than those 
of low-dose ICSs.57 Leukotriene modifiers provide partial 
protection against exercise-induced bronchoconstriction.56,57 As 
add-on treatment in children whose asthma is insufficiently 
controlled by low doses of inhaled glucocorticosteroids, 
leukotriene modifiers provide moderate clinical improvements, 
including a significant reduction in exacerbations52,58,59 
(Evidence B).
Children younger than 5 years
LTRAs are safe and effective for treatment of asthma in young 
children, from as early as 6 months of age.60-66 LTRAs have been 
proposed as alternative first-line therapy to ICSs for episodic or 
mild persistent asthma67 (Evidence D), particularly in children 
who have difficulty in utilising inhalation treatment, with 
poor compliance, or where exercise-induced bronchospasm 
(EIB) is a dominant component of asthma. To date, no studies 
have evaluated the role of LTRAs as add-on therapy to inhaled 
steroids in children ≤5 years old.
Asthma and allergic rhinitis are frequently co-morbid 
conditions (80%); however, both are often treated as separate 
entities. With the concept of the ‘united airway’ disease 
in which asthma and allergic rhinitis are regarded as 
manifestations of a single disorder, treating one disease may 
affect the control of the other. In certain countries (but not 
in South Africa), LTRAs are approved for treatment of both 
allergic rhinitis and asthma.68-70
7.6.4 Theophylline
Theophylline has been used in the treatment of asthma 
mainly as a bronchodilator (10 - 20 mg/kg/day), though 
it may also have anti-inflammatory effects at lower doses 
(5 - 10 mg/kg/day).71-74 However, the anti-inflammatory 
effects of theophylline are small (less than that of low-dose 
ICSs) and side-effects are common.75 Theophylline may 
be used as alternative, adjunctive therapy with ICSs in 
children >5 years old (Evidence D).74 Monitoring of serum 
theophylline concentration is essential. Long-term treatment 
with theophylline is not generally recommended in young 
children because of its adverse effects.
Table IX. Combination products available in South Africa
Combination  Device  Dose (µg)
Salmeterol/fluticasone DPI (Accuhaler) 50/100
     50/250
     50/500
Salmeterol/fluticasone MDI CFC-free 25/50
     25/125
     25/250
Formoterol/budesonide DPI (Turbuhaler) 4.5/80
     4.5/160
     9/320
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Side-effects
The most common side-effects of theophylline are anorexia, 
nausea, vomiting and headache. Mild central nervous 
stimulation, palpitations, tachycardia, arrhythmias, abdominal 
pain, diarrhoea and, rarely, gastric bleeding may also occur. 
These side-effects are mainly seen at doses >10 mg/kg/
day. The risk of adverse effects is reduced if treatment is 
initiated with daily doses around 5 mg/kg/day and then 
gradually increased to 10 mg/kg/day. Severe overdosing with 
theophylline can be fatal.
7.6.5 Oral corticosteroids
Oral corticosteroids such as prednisone may be considered 
in patients with poorly controlled severe asthma on optimal 
doses of ICS and additional controller therapy (Evidence 
D).19,34,76 Oral corticosteroids, while relatively inexpensive, are 
associated with serious systemic side-effects including growth 
suppression, obesity and adrenal suppression. Because of the 
side-effects of prolonged use of oral steroids, these agents 
should only be used for acute exacerbations, and then only 
for a maximum of 5 - 7 days at a dose of 1 - 2 mg/kg/dose 
of prednisone given once daily. It is not necessary to taper 
oral steroids if used as a short course. Maintenance treatment 
with daily or alternate-day oral steroids is indicated only in 
those patients not controlled with high-dose inhaled steroids 
and additional controller therapy. In children on oral steroids, 
increased dosage should be given during episodes of increased 
stress, e.g. surgery.
8. Other treatment options
8.1 Immunotherapy
The Expert Panel of the USA’s Department of Health and 
Human Services76 recommends that allergen immunotherapy 
be considered for patients who have persistent asthma if 
there is clear evidence of a relationship between symptoms 
and exposure to an allergen to which the patient is sensitive 
(Evidence B).
A meta-analysis of 75 randomised placebo-controlled 
studies has confirmed the effectiveness of subcutaneous 
immunotherapy in asthma with a significant reduction in 
asthma symptoms and medication and with improvement in 
bronchial reactivity77 (Evidence A).
Immunotherapy is also effective for children when used 
sublingually78 (Evidence B). Sublingual immunotherapy is 
effective in paediatric patients with allergic rhinitis79 (Evidence 
A) and has an effect on inflammatory parameters and bronchial 
hyper-reactivity in asthmatic children sensitised to house 
dust mites80 (Evidence B). Although both subcutaneous and 
sublingual immunotherapy are effective in asthmatic children 
(monosensitive to house dust mite or pollen), the latter is safer 
(confirmed in post-marketing studies81) (Evidence B). Based 
on the above evidence, sublingual immunotherapy could be 
used as adjunctive treatment to pharmacotherapy in children 
>5 years old with rhinitis and mild to moderate asthma (FEV1 
>80%), to enhance asthma control and, in some cases, effect a 
cure.
8.2 Omalizumab
Omalizumab (anti-IgE) is a monoclonal antibody that prevents 
binding of IgE to the high-affinity receptors on basophils 
and mast cells. Anti-IgE is used as adjunctive therapy for 
patients ≥12 years old with severe persistent asthma who have 
sensitivity to relevant inhalant allergens, e.g. house dust mite, 
cockroach, cat and dog. Isolated cases of anaphylaxis to anti-
IgE have been reported in adults. Omalizumab is administered 
via subcutaneous injection every 2 - 4 weeks. The therapeutic 
index of this agent in children is still being defined. Clinicians 
who administer omalizumab should be prepared and equipped 
to identify and treat anaphylaxis that may occur. Anti-IgE 
should preferably be administered by a specialist. Mode of 
administration and cost could limit the use of this treatment, 
particularly in children.
8.3 Macrolides
Macrolide antibiotics have recognised anti-inflammatory 
properties in addition to their antimicrobial effects. Although 
some benefits have been reported in adults with chronic 
persistent asthma, a meta-analysis of 7 randomised controlled 
clinical trials involving both children and adult patients 
(N=416) with chronic asthma and treated with macrolides or 
placebo for >4 weeks, reported insufficient evidence to support 
their use in patients with chronic asthma.82
8.4 Antihistamines
Antihistamines have no proven benefit for asthma symptom 
control, but may be useful for control of symptoms of co-
existing allergic diseases such as rhino-conjunctivitis, urticaria 
and atopic eczema.
8.5 Unnecessary therapy
The following are of no benefit in the treatment of childhood 
asthma: antibiotics, cough syrups, mucolytics, ionisers 
and breathing exercises. Complementary and alternative 
medications and interventions bear insufficient evidence 
to permit recommendations. Physiotherapy is indicated in 
children only where lobar collapse is documented.
9. Self-management plan for asthma
The responsibility for patient education rests with the doctor, 
and should be shared with trained health care professionals. 
Patients and parents must be encouraged to participate actively 
in their own management. In South Africa, the National 
Asthma Education Programme (NAEP) provides free access to 
patient educational materials as well as symptom/adherence 
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diaries and a self-management action plan. These are available 
at www.asthma.co.za.
Patient education significantly improves asthma control and 
decreases hospitalisation rates (Evidence A).83 The influence  
of education is greater in moderate-severe, compared with 
mild-moderate, asthma. Intensive education is of greater 
benefit than limited education, and written plans are superior 
to oral instructions. Education given at follow-up visits is 
more effective than education during emergency visits.84 
Culture-specific programmes for adults and children from 
minority groups with asthma are more effective than generic 
programmes in improving quality of life, asthma knowledge, 
asthma exacerbations and asthma control (Evidence B).85
Educational programmes should be considered a part of 
the routine care of all patients with asthma. Asthma self-
management education should be integrated into all aspects 
of asthma care and reinforced at each follow-up visit. The 
elements of a self-management plan are summarised as 
follows:
•    Avoid known allergens and nonspecific triggers, 
particularly tobacco smoke.
•    Educate patients and parents about asthma and its 
treatment, e.g. difference between controller and reliever 
treatment, correct use of inhalers, use of a spacer where 
necessary, and correct use of peak flow meter where 
appropriate.
•    Provide patients and parents with an asthma adherence and 
symptom diary as a tool for monitoring asthma control.
•    Provide all patients with a written action plan that includes 
instructions for both daily management (long-term control 
medication, if appropriate, and environmental control 
measures) and actions to manage worsening asthma (what 
signs, symptoms and PEF measurements (if used) indicate 
worsening asthma; what medications to take in response; 
what signs and symptoms indicate the need for immediate 
medical care). Written action plans are particularly 
recommended for patients who have moderate or severe 
persistent asthma, or a history of severe exacerbations, or 
poorly controlled asthma.
•    Arrange for a Medic-Alert badge for patients with severe 
steroid-dependent asthma, known drug hypersensitivity 
such as aspirin sensitivity, and brittle asthma.
10. Follow-up and review
Re-evaluate treatment within 2 - 6 weeks and adjust therapy 
as appropriate. The main objective of follow-up visits is to 
determine whether asthma is controlled or not (Table V). In 
addition, the following points should be assessed/monitored at 
each visit:
•   inhaler technique
•   adherence
•   written action plan
•   patient concerns
•   side-effects of medication
•   growth (weight, height).
11. Adjusting therapy based on control 
(Fig. 1)
If asthma is uncontrolled, treatment may be stepped up as 
follows:
•    For children younger than 5 years: If asthma is not 
controlled on low-dose ICS, doubling the initial dose of 
ICS (medium-dose ICS) is the preferred controller option. 
Alternatively, consider adding a LTRA or LABA (LABA 
approved only in children >4 years old) to the ICS. If 
uncontrolled on medium-dose ICS and a LTRA (or LABA 
in children >4 years old), refer to a specialist for further 
evaluation and management.
•    For children older than 5 years: Options for stepping up 
treatment include increasing the dose of ICS (medium dose) 
or adding a LABA or LTRA. If still uncontrolled, consider 
further increasing the ICS dosage or adding another 
controller therapy if already on medium doses of ICS.20 If 
still uncontrolled, refer to a specialist.
The need for additional treatment should be re-evaluated at 
each visit and maintained for as short a period as possible.
If asthma is well controlled for at least 3 months, reduce 
treatment. There are few studies to guide step-down therapy. A 
suggested regimen for step-down treatment is: first discontinue 
oral steroids; next reduce the dosage of ICS (if on high dose); 
and thereafter discontinue additional controller treatment. The 
child should be maintained on the lowest effective dose of ICS. 
Assess control on a regular basis.
There are many factors in poor asthma control (Table X), 
including lack of adherence, incorrect inhaler technique, 
inadequate therapy for the degree of severity of asthma, 
environmental triggers, and presence of co-morbid conditions. 
Alternative causes of recurrent wheezing must also be sought. 
Before stepping up or changing treatment, these factors should 
be excluded.
Table X. Reasons for poor asthma control (Evidence A)
Lack of adherence to controller medication
Inability to use inhaler or powder device correctly
Inadequate drug dosage
Ongoing allergen exposures
Uncontrolled allergic rhinitis/sinusitis
Gastro-oesophageal reflux
Psychosocial problems (family dysfunction, behaviour 
problems, depression)
Use of medications with adverse events (e.g. β-blockers, aspirin, 
NSAIDs)
Incorrect diagnosis
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Fig. 1. Adjusting treatment of asthma based on control.
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12. Non-adherence
Studies of adults and children have shown that approximately 
50% of those on long-term therapy fail to take medications 
as directed at least part of the time.86 Non-adherence may be 
defined in a non-judgemental way as failing to take treatment 
as agreed upon by the patient and the health care professional. 
Non-adherence may be identified by prescription monitoring, 
pill counting or drug assay, but at a clinical level it is best 
detected by asking about therapy in a way that acknowledges 
the likelihood of incomplete adherence (e.g. ‘So that we may 
plan therapy, do you mind telling me how often you actually 
take the medicine?’ or ‘How many times in a normal week do 
you forget to take the medicine?’). Specific drug and non-drug 
factors involved in non-adherence are listed in Table XI.
Strategies to promote adherence include:
•    prescribing a simple dosage regimen (once or twice daily) 
and as few drugs as possible
•    selecting treatment that achieves outcomes and addresses 
preferences that are important to the patient, and reminding 
patients that adherence will help to achieve goals of 
treatment
•    assessing the patient’s and family’s level of social support, 
and encourage family involvement
•    tailoring the self-management approach to the needs and 
literacy levels of the patient, and maintaining sensitivity to 
cultural beliefs and ethno-cultural practices. Individualised 
self-management of asthma has been shown to improve 
medication adherence and asthma control.87
13. Co-morbid conditions
It is necessary to identify and treat co-morbid conditions, 
such as those below, that may affect asthma control. If these 
conditions are treated appropriately, asthma control may 
improve.
•    Rhinitis or sinusitis symptoms or diagnosis should be 
evaluated in patients who have asthma, because of the 
interrelationship of the upper and lower airways. There 
is sufficient evidence that co-existing allergic rhinitis or 
sinusitis may impair asthma control in adults.88 In addition, 
therapy for allergic rhinitis or sinusitis has been shown 
to improve asthma control. Treatment of allergic rhinitis 
includes intranasal corticosteroids, antihistamine therapy, 
and, in selected cases, immunotherapy.89 Treatment of 
sinusitis includes intranasal corticosteroids and antibiotics. 
Evidence is inconclusive regarding the effect of sinus 
surgery on asthma in patients with chronic rhinosinusitis.
•    Gastro-oesophageal reflux disease (GORD) treatment may 
benefit patients who have asthma and complain of frequent 
heartburn, particularly those who have frequent nocturnal 
asthma symptoms. Even in the absence of suggestive GORD 
symptoms, consider evaluation for GORD in patients who 
have poorly controlled asthma.
•    Allergic bronchopulmonary aspergillosis may be 
considered in patients who have asthma and a history of 
pulmonary infiltrates, have IgE sensitisation to Aspergillus, 
and/or are corticosteroid-dependent. Diagnostic criteria 
include a positive immediate skin test and elevated serum 
IgE and/or IgG to Aspergillus and central bronchiectasis.
•    Obese patients who have asthma may be advised that 
weight loss, in addition to improving overall health, could 
also improve asthma control.
•    Stress and depression that not well controlled should 
be considered in patients who have asthma. Additional 
education to improve self-management and coping skills 
may be helpful. Referral to a child psychiatrist/psychologist 
may be necessary.
14. Referral to a specialist
The majority of asthmatics can be managed optimally in a 
primary health care facility, provided that the elements of the 
asthma guideline are followed. Some patients may require 
referral to a specialist; this is recommended if the goals of 
management are not achieved, or for the following reasons:
•   diagnosis is in doubt
•   unstable asthma
Table XI. Factors involved in non-adherence
Drug factors       Non-drug factors
Difficulties with inhaler devices     Misunderstanding or lack of instruction
Awkward regimens (e.g. four times daily or multiple drugs)   Fears about side-effects
Side-effects       Dissatisfaction with health care professionals
Cost of medication       Unexpressed/undiscussed fears or concerns
Dislike of medication      Inappropriate expectations
        Poor supervision, training or follow-up
        Anger about condition or its treatment
        Underestimation of severity
        Cultural issues
        Stigmatisation
        Forgetfulness or complacency
        Attitudes toward ill health
910
December 2009, Vol. 99, No. 12  SAMJ
•   parents or general practitioners need further support
•    child on a high dose of ICS (>400 µg beclomethasone 
equivalent per day)
•   oral steroids are required regularly
•   after a life-threatening episode
•   frequent hospitalisations or visits to an emergency room
•   if immunotherapy or omalizumab is considered.
Disclaimer
This national clinical guideline is for reference and educational 
purposes only and is not intended to be a substitute for the 
advice of appropriate health care professionals or for independent 
research and judgement. Some of the medications mentioned 
in this guideline are used off-label but with the best evidence 
available.
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Appendix B: Evidence grades and levels used in 
this guideline
Grade  Definition
A   Scientific evidence from randomised 
controlled trials (RCTs) in the target 
population, with statistically significant 
results that consistently support the 
guideline recommendations; supported 
by level 1 or 2.
B   Scientific evidence from well-designed, 
well-conducted observational studies in 
the target population, with statistically 
significant result consistently supporting 
the guideline recommendation; 
supported by level 3 or 4 evidence. 
Alternatively, extrapolated evidence from 
RCTs of populations (level 1 or 2) other 
than the target (paediatric) population. 
C   Scientific evidence from laboratory 
studies, animal studies or case studies; 
supported by level 5 evidence. 
D   Expert opinion providing the basis for 
the guideline recommendation. Scientific 
evidence either inconsistent or lacking. 
Level
1  Well-conducted and designed RCT
2  RCT with significant threats to validity
3   Observational study with a concurrent 
control group
4   Observational study with historical 
control
5  Bench study, animal study, or case series
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